rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Biomerica, Inc.

BMRA · Nasdaq

Health CareDiagnostics & LabsNot moving yet

BMRA stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 14.6% below that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+5 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 2
Industry in uptrend
52% +5 in 4 wk
Insider buys, 12 months
$316K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
19 (+9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

21 Apr – 20 Oct
16%34%53%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$305KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers5 · 0
WhoDidSharesTraded
Zackary S. IraniChief Executive Officerbought31,250at $1.6026 Aug 2026filed 27 Aug 2026
Allen BarbieriExecutive Vice Chairmanbought20,000at $1.6026 Aug 2026filed 27 Aug 2026
Eric ChinDirectorbought6,250at $1.6026 Aug 2026filed 27 Aug 2026
David MoatazediDirectorbought10,000at $1.6026 Aug 2026filed 27 Aug 2026
M. Huff GaryDirectorbought31,250at $1.6020 Aug 2026filed 27 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders19+9 on the quarter
New · exited9 · 0
Reported value$174K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202624,347$43K-31,695−56.6%
BlackRock, Inc.unchanged · filed 7 Aug 202618,636$33K00.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202614,514$26K00.0%
JANE STREET GROUP, LLCnew · filed 14 Aug 202612,640$22K+12,640
LPL Financial LLCunchanged · filed 7 Aug 202610,849$19K00.0%
UBS Group AGadded · filed 13 Aug 20266,951$12K+6,432+1239.3%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 20266,613$12K00.0%
NewEdge Advisors, LLCnew · filed 12 Aug 20263,603$6,341+3,603
Tower Research Capital LLC (TRC)new · filed 11 Aug 2026238$419+238
HOLLENCREST CAPITAL MANAGEMENTreduced · filed 13 Aug 2026200$352-625−75.8%
31 Mar 2023 – 30 Jun 2026
112233Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Allen Barbieri Company insiderExecutive Vice Chairman · last 26 Aug 20264 · 0
David Moatazedi Company insiderDirector · last 26 Aug 20261 · 0
Eric Chin Company insiderDirector · last 26 Aug 20261 · 0
Zackary S. Irani Company insiderChief Executive Officer · last 26 Aug 202638 · 0
M. Huff Gary Company insiderDirector · last 20 Aug 20261 · 0
Gary Lu Company insiderChief Financial Officer · last 12 Dec 20250 · 0
Catherine Coste Company insiderDirector · last 13 Dec 20242 · 0
Jane Emerson Company insiderDirector · last 13 Dec 20241 · 0
John P. Kenny Company insiderDirector · last 13 Dec 20230 · 0
Mark A. Sirgo Company insiderDirector · last 9 Dec 20213 · 2
Steven Sloan Company insiderChief Financial Officer · last 9 Dec 20210 · 0
Francis Cano Company insiderDirector · last 10 Dec 20207 · 0

Same industry

CDNA CareDxLeading+94%
NTRA NateraLeading+49%
XGN ExagenLeading+41%
PSNL PersonalisLeading+36%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 31 May 20268.1%
Operating profit marginFY 2026 · to 31 May 2026-119%
Return on capital employedFY 2026 · to 31 May 2026-124%
Research spendFY 2026 · to 31 May 202617.7%
Share count trendFY 2026 · to 31 Aug 202643.6%
Cash and equivalentsFY 2026 · to 31 May 2026$1.3M

Analyst forecasts

No analyst forecasts yet.